Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilorasertib in CDKN2A-deficient Advanced Solid Cancers
NCT02540876Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Sep 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ilorasertib in solid tumor (advanced stage), sponsored by University of Chicago. Primary endpoint: Change in tumor burden at 22 weeks. Started Sep 2015; status: completed.
02
Drugs
ilorasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02540876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540876.